Northstar Advisory Group LLC Sells 5,807 Shares of Stryker Corporation $SYK

Northstar Advisory Group LLC reduced its holdings in Stryker Corporation (NYSE:SYK) by 57.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,335 shares of the medical technology company’s stock after selling 5,807 shares during the quarter. Northstar Advisory Group LLC’s holdings in Stryker were worth $1,715,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Advance Capital Management Inc. grew its position in shares of Stryker by 5.8% in the 2nd quarter. Advance Capital Management Inc. now owns 1,186 shares of the medical technology company’s stock worth $469,000 after buying an additional 65 shares during the last quarter. Canandaigua National Bank & Trust Co. boosted its position in shares of Stryker by 2.5% during the second quarter. Canandaigua National Bank & Trust Co. now owns 8,302 shares of the medical technology company’s stock valued at $3,285,000 after purchasing an additional 206 shares in the last quarter. Apella Capital LLC boosted its position in shares of Stryker by 1.3% during the second quarter. Apella Capital LLC now owns 4,927 shares of the medical technology company’s stock valued at $1,934,000 after purchasing an additional 64 shares in the last quarter. Heartwood Wealth Advisors LLC boosted its position in shares of Stryker by 24.9% during the second quarter. Heartwood Wealth Advisors LLC now owns 803 shares of the medical technology company’s stock valued at $318,000 after purchasing an additional 160 shares in the last quarter. Finally, Quintet Private Bank Europe S.A. boosted its position in shares of Stryker by 8.5% during the second quarter. Quintet Private Bank Europe S.A. now owns 6,942 shares of the medical technology company’s stock valued at $2,746,000 after purchasing an additional 541 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Citigroup reissued a “buy” rating and issued a $455.00 target price (up from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Friday, July 18th. BTIG Research reissued a “buy” rating on shares of Stryker in a report on Monday, July 14th. Needham & Company LLC upped their price target on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, Evercore ISI upped their price objective on Stryker from $390.00 to $415.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $431.42.

Stryker Stock Performance

Shares of SYK opened at $383.32 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The business has a 50-day simple moving average of $388.98 and a two-hundred day simple moving average of $379.50. The stock has a market cap of $146.55 billion, a price-to-earnings ratio of 50.77, a PEG ratio of 2.76 and a beta of 0.93. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter in the prior year, the business posted $2.81 earnings per share. The business’s quarterly revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.